Fibroblast-derived Neuregulin 1 Promotes Compensatory ErbB3 Receptor Signaling in Mutant BRAF Melanoma

BRAF Inhibition Stimulates Melanoma-Associated Macrophages to Drive Tumor Growth

(2015) T. Wang et al.   CLINICAL CANCER RESEARCH

Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells

(2015) I V Fedorenko et al.   ONCOGENE

Function-Blocking ERBB3 Antibody Inhibits the Adaptive Response to RAF Inhibitor

(2014) C. H. Kugel et al.   CANCER RESEARCH

Twist1 Is a Key Regulator of Cancer-Associated Fibroblasts

(2014) K.-W. Lee et al.   CANCER RESEARCH

Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma

(2014) Edward J. Hartsough et al.   MOLECULAR CANCER RESEARCH

Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation

(2014) Miao-chong J. Lin et al.   MOLECULAR CANCER RESEARCH

Adaptive resistance to RAF inhibitors in melanoma

(2014) Curtis H. Kugel et al.   Pigment Cell & Melanoma Research

Inhibition of mutant BRAF splice variant signaling by next-generation, selective RAF inhibitors

(2014) Kevin J. Basile et al.   Pigment Cell & Melanoma Research

Intrinsic Resistance to MEK Inhibition in KRAS Mutant Lung and Colon Cancer through Transcriptional Induction of ERBB3

(2014) Chong Sun et al.   Cell Reports

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110  Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers

(2013) J. T. Garrett et al.   CANCER RESEARCH

In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors

(2013) K. J. Basile et al.   CANCER RESEARCH

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin

(2013) A. P. Garner et al.   CANCER RESEARCH

Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3

(2013) Ethan V. Abel et al.   JOURNAL OF CLINICAL INVESTIGATION

Stat3-Targeted Therapies Overcome the Acquired Resistance to Vemurafenib in Melanomas

(2013) Fang Liu et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Resistance to RAF Inhibitors Revisited

(2013) Edward Hartsough et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

An ERBB3/ERBB2 oncogenic unit plays a key role in NRG1 signaling and melanoma cell growth and survival

(2013) Keman Zhang et al.   Pigment Cell & Melanoma Research

Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells

(2013) Kaitlyn Le et al.   Pigment Cell & Melanoma Research

Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF -Mutant Thyroid Carcinomas

(2013) Cristina Montero-Conde et al.   Cancer Discovery

Carcinoma-Associated Fibroblasts Are a Promising Therapeutic Target

(2013) Shinsaku Togo et al.   Cancers

Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

(2012) Piro Lito et al.   CANCER CELL

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

(2012) Ravid Straussman et al.   NATURE

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors

(2012) Timothy R. Wilson et al.   NATURE

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Notch1–neuregulin1 autocrine signaling loop contributes to melanoma growth

(2012) K Zhang et al.   ONCOGENE

Inhibiting EGF Receptor or SRC Family Kinase Signaling Overcomes BRAF Inhibitor Resistance in Melanoma

(2012) Maria R. Girotti et al.   Cancer Discovery

Targeting ErbB3-mediated stromal–epithelial interactions in pancreatic ductal adenocarcinoma

(2011) J S Liles et al.   BRITISH JOURNAL OF CANCER

Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options

(2011) J. Villanueva et al.   CANCER RESEARCH

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)

(2011) Poulikos I. Poulikakos et al.   NATURE

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

A recombinant decoy comprising EGFR and ErbB-4 inhibits tumor growth and metastasis

(2011) M Lindzen et al.   ONCOGENE

An Activated ErbB3/NRG1 Autocrine Loop Supports In Vivo Proliferation in Ovarian Cancer Cells

(2010) Qing Sheng et al.   CANCER CELL

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

The fibroblast-derived paracrine factor neuregulin-1 has a novel role in regulating the constitutive color and melanocyte function in human skin

(2010) W. Choi et al.   JOURNAL OF CELL SCIENCE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

(2010) Ramin Nazarian et al.   NATURE

Hyperactivation of MEK–ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells

(2010) F M Kaplan et al.   ONCOGENE

PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells

(2010) Ruth Halaban et al.   Pigment Cell & Melanoma Research

NRG1 / ERBB3 signaling in melanocyte development and melanoma: inhibition of differentiation and promotion of proliferation

(2009) Kristina Buac et al.   Pigment Cell & Melanoma Research

HER3 Is a Determinant for Poor Prognosis in Melanoma

(2008) M. Reschke et al.   CLINICAL CANCER RESEARCH

Neuregulin 1 in neural development, synaptic plasticity and schizophrenia

(2008) Lin Mei et al.   NATURE REVIEWS NEUROSCIENCE